РОЛЬ НЕЙРОПРОТЕКТОРНОЙ ТЕРАПИИ ПРИ ЛЕЧЕНИИ ГЛАУКОМНОЙ ОПТИЧЕСКОЙ НЕЙРОПАТИИ

Ф. А. Мирбабаева

Передовая Офтальмология · 2023-yil

Annotatsiya

Annotation. Relevance. To date, it is urgent to search for effective methods of complex treatment with the use of neuroprotectors and bioregulators to reduce the rate of progression of GON (glaucoma optic neuropathy). The purpose of the study. To study the effect of choline alphoscerate on the structure of the optic nerve and the peripapillary layer of retinal nerve fibers in the complex treatment of patients with POAG. Material and methods. The study included 88 patients (125 eyes) with POAG (with compensated IOP), including 34 men and 54 women. The patients were divided into 2 groups: group 1 (main, neuroprotective treatment) — 63 eyes (42 patients with POAG, average age — 63.28±9.86 years). IOP was compensated in all patients before treatment (mean P0 was 19.0 (17.0–21.0) mmHg). Patients of this group underwent complex therapy of GON with the neuroprotective drug Gliatilin (intravenously) in combination with the Retinalamine biopeptide (parabulbarno) for 10 days. Group 2 (control) — 65 eyes (46 patients with POAG, average age — 64.65± 9.85 years). Before treatment, the average P0 in the group was 18.7 (16.5–21.0) mm Hg. patients in this group underwent complex treatment, which included the use of Retinalamine in the form of parabulbar injections for 10 days. Results and conclusion. Neuroprotective treatment with Gliatilin contributes to the improvement of structural parameters in patients with glaucoma: a significant increase in the total thickness of the peripapillary SNVS was revealed from 82.88 (61.62–94.17) to 89.33 (65.47–98.99) microns (p<0.001, 7.78%) in the main group after treatment.

Maqola ma’lumotlari
MualliflarФ. А. Мирбабаева
JurnalПередовая Офтальмология
Nashr sanasi2023-11-28
Jild5
Son5
Betlar30-33
Tilru
DOI10.57231/j.ao.2023.5.5.005

Передовая Офтальмология jurnalidan boshqa maqolalar

Передовая Офтальмология — barcha maqolalar